https://test2.mooswinkel.de/new-standard-for-parkinsons-diagnostics-german-biotech-company-modag-unveils-worlds-first-ce-certified-test-kit/ 2026-03-15T23:02:41+00:00 https://test2.mooswinkel.de/wp-content/uploads/2026/03/MODAG-Pressemitteilung-PD-DETECT.png https://test2.mooswinkel.de/wp-content/uploads/2026/03/PD_Detect_Box_02_16-9.jpeg https://test2.mooswinkel.de/neuer-standard-fuer-die-parkinson-diagnostik-rheinland-pfaelzer-biotech-unternehmen-modag-stellt-weltweit-erstes-ce-zertifiziertes-test-kit-vor/ 2026-03-15T23:01:16+00:00 https://test2.mooswinkel.de/wp-content/uploads/2026/03/MODAG-Pressemitteilung-PD-DETECT.png https://test2.mooswinkel.de/wp-content/uploads/2026/03/PD_Detect_Box_02_16-9.jpeg https://test2.mooswinkel.de/biotechnologieunternehmen-modag-aus-rheinland-pfalz-erhaelt-forschungsfoerderung-von-der-michael-j-fox-foundation/ 2026-01-09T11:44:57+00:00 https://test2.mooswinkel.de/wp-content/uploads/2026/01/20251212_MODAG-erhaelt-Forschungsfoerderung-der-Michael-J-Fox-Foundation_800px.jpg https://test2.mooswinkel.de/rhineland-palatinate-biotech-company-modag-receives-research-grant-funding-from-the-michael-j-fox-foundation/ 2026-01-09T11:40:15+00:00 https://test2.mooswinkel.de/wp-content/uploads/2026/01/20251212_MODAG-erhaelt-Forschungsfoerderung-der-Michael-J-Fox-Foundation_800px.jpg https://test2.mooswinkel.de/teva-and-modag-announce-licensing-collaboration/ 2025-09-25T09:41:39+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/06/Teva-und-MODAG-geben-Lizenzkooperation-fuer-Wirkstoffkandidaten-gegen-neurodegenerative-Erkrankungen-bekannt_V2_DE-1.webp https://test2.mooswinkel.de/rhineland-palatinate-biotech-company-modag-gmbh-celebrates-fast-track-designation-in-the-usa/ 2025-09-10T08:31:12+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/09/20250909_MODAG_FDA_Fast-Track_Emrusolmin_DE_thumbnail_800px.webp https://test2.mooswinkel.de/rheinland-pfaelzer-biotech-unternehmen-modag-gmbh-feiert-fast-track-designation-in-den-usa/ 2025-09-10T08:18:48+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/09/20250909_MODAG_FDA_Fast-Track_Emrusolmin_DE_thumbnail_800px.webp https://test2.mooswinkel.de/modag-starts-phase-1b-study-for-anle138b-in-parkinsons-patients/ 2025-06-03T12:22:32+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/06/20201223_MODAG_TrialStart_FiP_1b_PR_final_EN-1.webp https://test2.mooswinkel.de/modag-successfully-completes-phase-1-trial-for-neurodegenerative-diseases/ 2025-06-03T12:00:34+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/06/202000805_MODAG_anle138b_TrialCompletion_MJF_Funding_English-1.webp https://test2.mooswinkel.de/modag-starts-first-clinical-phase-1-study-with-anle138b/ 2025-06-03T11:31:13+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/01/20191218_MODAG_TrialStart_DE_Page_1-copy.webp https://test2.mooswinkel.de/modag-appoints-dr-johannes-levin-as-chief-medical-officer/ 2025-06-03T10:26:27+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/06/20190904_MODAG_CMO_EN_Final-1.webp https://test2.mooswinkel.de/modag-closes-eur-12-million-series-a-financing-round/ 2025-06-03T10:02:28+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/06/20190627_pressrelease_modag_series_a_EN-1.webp https://test2.mooswinkel.de/teva-und-modag-geben-lizenzkooperation-bekannt/ 2025-06-03T09:10:52+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/06/Teva-und-MODAG-geben-Lizenzkooperation-fuer-Wirkstoffkandidaten-gegen-neurodegenerative-Erkrankungen-bekannt_V2_DE-1.webp https://test2.mooswinkel.de/modag-schliesst-erfolgreich-phase-1-studie-fuer-neurodegenerative-erkrankungen-ab/ 2025-04-29T09:48:42+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/01/202000805_MODAG_anle138b_TrialCompletion_MJF_Funding_Deutsch.webp https://test2.mooswinkel.de/modag-ernennt-dr-johannes-levin-zum-chief-medical-officer/ 2025-04-29T06:59:28+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/01/20190904_MODAG_CMO_DE_Final_Page_1-copy.webp https://test2.mooswinkel.de/modag-schliesst-12-mio-eur-serie-a-finanzierungsrunde-ab/ 2025-04-29T06:57:18+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/01/20190627_pressemeldung_modag_series_a_Page_1-copy.webp https://test2.mooswinkel.de/modag-startet-erste-klinische-phase-1-studie-mit-anle138b/ 2025-04-29T06:52:20+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/01/20191218_MODAG_TrialStart_DE_Page_1-copy.webp https://test2.mooswinkel.de/modag-startet-phase-1b-studie-fuer-anle138b-bei-parkinson-patienten/ 2025-04-29T06:48:10+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/01/20201223_MODAG_TrialStart_FiP_1b_PR_final_deutsch_Page_1-copy.webp https://test2.mooswinkel.de/innovations-in-neurology/ 2025-04-28T15:16:59+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/01/anle_138b_05_BGlarge_R2025_1920x1080px_2.jpg https://test2.mooswinkel.de/innovationen-in-der-neurologie/ 2025-04-28T15:15:50+00:00 https://test2.mooswinkel.de/wp-content/uploads/2025/01/anle_138b_05_BGlarge_R2025_1920x1080px_2.jpg